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with only fair outcome, poor outcome, or even death are all considered just as having a bad outcome. Alternatively, one could consider if treatment shifted the entire distribution of outcomes favorably, that is, one seeks an increase in the average likelihood of achieving a better outcome. 1 The traditional measure for a good stroke outcome, modified Rankin Scale (mRS) score of 0 to 1, considers the former, whereas ordinal approaches generally consider the latter.
These 2 approaches are not mutually incompatible, however, and both should usually be considered. Indeed, a good clinician could incorporate elements of each approach when counseling patients or relatives before offering intravenous thrombolysis for stroke.
The recent individual patient data pooled analysis of 6756 patients from 9 thrombolysis trials reported treatment differences that dichotomized outcomes into the excellent (mRS, 0-1) and bad (death: mRS 6 versus 0-5) ends of the scale. 2 In those analyses, intravenous alteplase was shown to improve significantly the overall odds of an excellent stroke outcome (mRS, 0-1) when delivered within 4.5 hours of stroke onset. That analysis showed that earlier treatment resulted in larger benefit of treatment, with-at any given time delay-proportional treatment effects that were similar irrespective of age or stroke severity within the range studied. However, alteplase was also shown to increase the absolute risk of fatal intracranial hemorrhage within the first week by about 2%, with no significant effect on other early causes of death but perhaps partly offset by later causes of death.
An earlier individual patient data analysis carried out in 2010, which included data from 8 of the same 9 trials, suggested that 3-month mortality was increased when treatment was initiated beyond 4.5 hours after stroke onset, 3 but in the updated analysis, this trend with treatment delay lost statistical significance. However, death is just one potential adverse outcome: severe or even moderate disability will be considered by some patients to be as undesirable as death, or perhaps worse 4 ; and others still may consider any loss of dependence as a poor outcome. 5 In addition, differences in the length of hospital stay, and the cost of care, increase substantially and monotonically with measures of disability. 6 To help clinicians to discuss with their patients the pros and cons of a treatment that carries both potential risks and benefits, we now report various analyses that consider the full range of functional states 90 to 180 days after stroke.
For most circumstances in which the outcome measure involves a series of 3 or more levels of ordinal outcomes, ordinal analysis is generally considered a statistically powerful approach by expert groups for circumstances where treatment effects are not expected to concentrate at one end of the disability scale. 1, 7 For treatments that may have a dual effect (the extreme example would be kill or cure), risk and benefit may each be more reliably detected by a dichotomized analysis (symptom-free survival), but if survival despite continued symptoms is a desirable health state to some patients, then an analysis that considers all categories (symptom-free survival, symptomatic survival, severe disability, and death) may be more discriminating for net benefit. 1, 8 Because it is well established that later treatment (eg, 4.5-6 hours after stroke onset) is associated with reduced benefit and with a trend at least toward lower 90-day survival, we can surmise that the greatest treatment delay at which net benefit persists may be shorter than the ≈5-hour window when indexed by defining a good outcome as mRS score of 0 to 1.
2 However, the more sensitive ordinal analysis offers the opportunity to refine the characterization of the time period when patients benefit from alteplase therapy. The aim of this report is to present the results from the predefined ordinal analyses 9 and to put them in context with the already published main dichotomous ones.
2
Methods
The data sources and analysis methods have been described in detail previously, particularly the approach used to determine the influence of time from stroke onset on the outcome mRS score of 0 to 1 versus 2 to 6. 2, 9 For each other dichotomy of mRS, that is, 0 versus 1 to 6, 0 to 2 versus 3 to 6, etc, we repeated that approach. We also examined the full range of the mRS to assess the common odds of better outcome with intravenous alteplase versus control, using ordinal logistic regression. 10 The use of the common odds ratio invokes assumptions about the consistency of the treatment effect across the spectrum of outcome scores but carries advantages over its alternatives in terms of greater statistical power and ease of adjustment for baseline prognostic factors. 1, 8 However, we also applied the ordinal approach of Howard et al 11 that weights all steps of the mRS equally, to estimate the net benefit of treatment (ie, the expected number who would do better if given alteplase minus the expected number who would do worse), among a cohort with the case mix included in the pooled trials.
As described previously, regression models, which for dichotomized outcomes were stratified by trial, were adjusted for allocation to alteplase, treatment delay, age, stroke severity (as measured by the pretreatment National Institutes of Health Stroke Scale [NIHSS]), and relevant interaction term(s). 9 Adjusted models are needed because of the strong inter-relationships between age, treatment delay, and stroke severity in the 9 included trials. 2, 9 For example, patients treated earlier tended to be older and to have had more severe strokes than patients treated later. Eight trials assessed functional outcome after 3 months using the mRS, whereas the third international stroke trial (IST-3) applied the Oxford Handicap Scale to patients at 6 months' followup. [12] [13] [14] [15] [16] [17] [18] Whereas our publication on mRS score of 0 to 1 described functional outcome at 3 to 6 months, but mortality only at 3 months, for the present analyses we have used mortality and functional outcome at 6 months for IST-3 patients but at 3 months for all other trials' patients (noting that a 3-month assessment was not performed in IST-3). 2 Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) and R version 2.11.1 (https://www.R-project.org).
Where relevant, the significance of 3-way interaction terms was assessed using the likelihood ratio test of the change in deviance between 2 nested models that differed only by the relevant interaction term. We made no adjustment for multiplicity: ordinal analysis was planned, 9 and the primary dichotomized analysis of mRS score of 0 to 1 achieved statistical significance.
Results
The baseline characteristics of the patient population are provided in Table. There were 6756 patients with mean (SD) age 71±13 years, NIHSS 12±7, and onset to treatment delay 4.0±1.2 hours.
The average odds of achieving a better stroke outcome in alteplase-allocated compared with control-allocated patients across the whole 6-hour window (mean delay 4.0 hours) diminished as the selected cut point used to define better outcome shifted from asymptomatic (mRS, 0 versus 1-6; odds ratio, 1.40; 95% confidence interval [CI], 1.22-1.62) to greatest residual disability (mRS, 0-5 versus 6; odds ratio, 0.93; 95% CI, 0.82-1.06; Figure 1 ). The P value for the assumption of a common odds ratio is <0.0001, suggesting that there is heterogeneity of the odds ratios across the various dichotomies. This heterogeneity between mRS thresholds would
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seem to be attributable to a general downward shift in the odds of better outcome at higher mRS thresholds, whereas the pattern of poorer outcomes with longer delays in the time to treatment was relatively consistent across the mRS spectrum. For each of the possible dichotomizations of mRS, earlier treatment was associated with bigger proportional benefits; this interaction with treatment delay was conventionally statistically significant (P<0.05) for each of the comparisons 0 to 1 versus 2 to 6 through to 0 to 4 versus 5 to 6, and, despite being qualitatively similar, with relatively few patients with mRS score of either 0 or 6 was not statistically significant for mRS score of 0 versus 1 to 6 or 0 to 5 versus 6 ( Figure 2 ). The maximum delay between stroke onset and treatment that was associated with a significantly positive treatment effect was at 
Age, y 66 (11) 68 (12) 65 (12) 66 (11) 66 (13) 66 (11) 65 (12) 72 (13) 77 (12) 71 (13 
Stroke severity (NIHSS) 14 (7) 15 (7) 12 (6) 12 (6) 13 (7) 11 (6) 10 (5) 13 (6) 12 (7) 12 (7) >0, ≤4 (14) 87 (13) 84 (13) 81 (14) 82 (14) 84 (14) 78 (13) 82 (15) 83 (14) Categorical data presented as n (%), continuous data presented as mean (SD). ATLANTIS indicates Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke; ECASS, European Cooperative Acute Stroke Study; EPITHET, Echoplanar Imaging Thrombolytic Evaluation Trial; IST, International Stroke Trial; and NINDS, National Institute of Neurological Disorders and Stroke.
*In IST-3, 244 patients had their baseline National Institutes of Health Stroke Scale (NIHSS) score predicted from other measurements recorded at their baseline assessment. Ignoring these patients, the numbers of IST-3 patients in each category of baseline NIHSS score above would be 385, 972, 531, 559, and 344, respectively.
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September 2016 least 4.5 hours for each dichotomization of the mRS classifying 0, 0 to 1, 0 to 2, or 0 to 3 as good outcome. For mRS score of 0 to 4 versus 5 to 6 or 0 to 5 versus 6 (death), it was not established that alteplase significantly increased the overall odds of a better outcome (Figure 1 ) nor that earlier treatment (even at 1 hour) was associated with a clear benefit (Figure 2) . After combining the results of the alternative dichotomous analyses to model the average odds ratio for any upwards shift in mRS, treatment initiation within 4.5 hours was associated with statistically significant net benefit, with earlier treatment resulting in bigger proportional benefits (Figure 3) . Given treatment delay, neither patient age nor baseline stroke severity significantly altered the proportional effect of alteplase on the odds of an improved outcome ( Figure I in the online-only Data Supplement) nor did stroke severity significantly alter the relationship between treatment delay and the odds of an improved outcome with alteplase (P=0.72). The test for a 3-way interaction among treatment, treatment delay, and age as a continuous variable had a P value of 0.0019, in the direction of older age lengthening the window during which intravenous alteplase may be effective ( Figure An ordinal analysis, avoiding the proportionality assumption, 11 of the patients treated within 4.5 hours of stroke onset (mean delay 3 hours 20 minutes), where benefit is expressed as any improvement in 1 or more divisions of the mRS, found that a net 55 patients (95% CI, 13-91) per 1000 treated were better with alteplase, P=0.004. Earlier treatment was better: within 3 hours (average 2 hours 20 minutes) net benefit was 122 patients (95% CI, 61-171) per 1000 treated, whereas initiating treatment beyond 4.5 hours (mean 5 hours 20 minutes) revealed a net benefit of only 20 patients (95% CI, −31 to 75) per 1000 treated, P=0.45.
Discussion
Patients with acute ischemic stroke show wide variation in the severity and range of their symptoms at presentation. Their functional outcomes are also diverse. The categories of the mRS capture this diversity well. Dichotomization of the scale at mRS score at 0 to 1 (excellent outcome) versus 2 to 6 (poorer outcome) or at 0 to 2 (independent) versus 3 to 6 (dependent or dead) simplifies the presentation of the impact of treatment, but implying cure or near cure oversimplifies clinical reality for most patients. Patients want to know whether treatment will make a noticeable difference to their functional outcome: many would regard an improvement by any step in mRS level as worthwhile, although they would not necessarily weight all transitions as equal. 5 In addition, such simplification tends to lead to situations where clinicians are eager to identify the good responders, whereas the reality may well be that the majority of patients improve somewhat, with a few showing a major improvement (or major deterioration and early death). An overemphasis on only treating those likely to have a major improvement may lead to the situation where the net benefit of thrombolysis would be lost.
Although all trials except IST-3 excluded patients with the most minor symptoms, our analysis reveals that if good outcome is represented by any contiguous group of mRS levels from 0 (asymptomatic) down to 3 (requiring help for activities of daily living), then the onset to treatment time window in which benefit is statistically more likely with alteplase is at least 4.5 hours, although earlier treatment is better and by 4.5 hours, the benefit is becoming small. Although generalizing these findings to those with the most minor symptoms (who were excluded from most trials) should be done with caution, our data cover a range of NIHSS from 4 (mean in bottom fifth of distribution) to 22 (top fifth mean). Within this, the uniformity of the proportional treatment effect across the spectrum of severity suggests a consistent effect. The absolute risk of bleeding is lower among patients with low NIHSS scores. Treatment with intravenous alteplase initiated within 4.5 hours reduces the proportion of patients with mRS score of ≥4: there will be fewer patients who cannot walk independently or require help with basic toileting. We neither found that intravenous alteplase alters mRS score of 0 to 4 versus 5 to 6 nor, as we have previously shown and examined in greater detail, 2 did we have evidence that it alters survival excepting the small excess of early fatal bleeding (Figures 1 and 2) . Thus, intravenous alteplase seems to enhance chances of achieving a good outcome by more than 
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it improves the chances of achieving a merely acceptable outcome, which may be attractive to patients. Analysis that relies on a common odds ratio to combine all possible dichotomies of mRS is compromised by violation of the assumption that these ratios are similar. However, although the odds ratios diminish as the criterion for good outcome drops toward greater disability, we do not have evidence that they invert. We found that if all categories of mRS are given equal weight and any net movement toward better outcome is regarded as desirable, then the onset to treatment window for benefit from intravenous alteplase is at least 4.5 hours, although earlier treatment is better than later treatment within this window. The ordinal approach 11 that avoids the proportionality assumption gives a comparable result. Neither age nor baseline stroke severity shortens the treatment time window for any relative benefit. Note that the 9 trials that we analyzed include many patients who would fall out with the labels for marketing authorizations that apply in the United States, Europe, and many other regions.
Because the magnitude of the treatment effect seems to decrease at higher thresholds (ie, 2 higher dichotomies show no significant benefit from intravenous alteplase irrespective of treatment initiation delay), it was anticipated that the ordinal analysis may not confirm benefit until 4.5 hours. However, there was a clear benefit for lower mRS thresholds, and only a lack of effect for higher mRS thresholds. In contradistinction, although alteplase has a neutral effect on mRS score of 0 to 4 versus 5 to 6 and on survival, there is still a strong trend toward a time-related effect for these mRS divisions, such that the treatment initiated within 3 hours seems more useful than the treatment initiation after 3 hours. This has biological plausibility.
The observed outcomes of the isolated cohorts of patients within each treatment delay window or severity category (Figures IV and V in the online-only Data Supplement) give a less reliable picture of treatment effects than the models that incorporate all data together because case mix varies between cohorts, and this has a strong influence on outcome and because smaller samples deliver lower statistical power. Relative odds of a good stroke outcome with alteplase by time to treatment, for each alternative definition of good outcome. In each panel, the solid line represents the best linear fit between the log odds ratio for each mRS outcome among patients given alteplase compared with patients given control (vertical axis) and treatment delay (horizontal axis). Estimates are derived from a regression model in which alteplase, time to treatment, age, and stroke severity (handled in a quadratic manner) are included as main effects but the only treatment interaction included is with time to treatment. CI indicates confidence interval; and mRS, modified Rankin Scale. Figure 3 . Effect of alteplase on any upwards shift in modified Rankin Scale (mRS), by treatment delay. The solid line represents the best linear fit between the log odds ratio for an improved stroke outcome among patients given alteplase compared with patients given control (vertical axis) and treatment delay (horizontal axis). Estimates are derived from a regression model in which alteplase, time to treatment, age, and stroke severity (handled in a quadratic manner) are included as main effects but the only treatment interaction included is with time to treatment. Only 198 patients (159 of whom were from International Stroke Trial-3 [IST-3]) had a time from stroke onset to treatment of >6 h. The point at which the estimated treatment effect crosses 1 is, therefore, an extrapolation from the data. CI indicates confidence interval.
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We also note that the design of the IST differed from other trials in 3 major ways: (1) it was open label treatment, whereas other trials were placebo controlled, (2) it assessed outcome after 6 months, rather than 3 months, and (3) it had a broader eligibility criteria and included patients outside of usual treatment guidelines. However, as previously reported, the results from IST-3 were consistent with those from the other trials, both for measures of benefit and for measures of harm (eg, for mRS, 0-1 versus 2-6, the P value for inconsistency between IST-3 and the other trials was 0.92). 19 Our current results extend our previous reports 2, 19 and are consistent with the conclusions of the individual trials that showed benefit within 4.5 hours of stroke onset, but especially within 3 hours. 12, 15 They also support the conclusions of the European Stroke Organisation Guidelines on stroke management. 20 We have not discussed here the early risk of fatal bleeding that is a well-recognized complication of intravenous alteplase treatment, 2, 19 because it has an impact neither on assessment of the outcome distribution nor, in the absence of a reliable means of identifying patients who will suffer an unacceptably high risk of bleeding, on the decision to treat. This does not detract from the importance of weighing risks and benefits when counseling patients.
Summary and Conclusions
The implications of our analysis that considers all levels of functional outcome including survival after stroke are that 1. on average, there is an increased chance of achieving an improved level of function if treatment with intravenous alteplase is initiated within 4.5 hours of stroke onset; 2. treatment benefit is greater with earlier initiation of treatment; 3. neither age nor stroke severity has a detectable impact on the relationship between delay and treatment benefit, and particularly not on the duration of the clinically justifiable treatment window; and 4. any patient who fulfils the criteria for treatment with alteplase and who wishes to optimize his chance of survival with optimal function should be offered treatment with intravenous alteplase as a matter of extreme urgency, ideally within a maximum initiation delay of 4.5 hours. The estimated odds ratio is plotted for patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 1.14 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test). In each panel, the solid line represents the best linear fit between the log of the common odds ratio (vertical axis) and treatment delay (horizontal axis). The estimates and their confidence intervals are derived from a proportional odds logistic regression model which adjusts for allocation to rtPA, age, treatment delay and stroke severity and, through inclusion of appropriate interaction terms, allows the log odds ratio to vary by treatment delay and for that relationship to itself differ between patients aged 80 years or younger and patients aged over 80 years.
Treatment delay (hours) Supplemental figure IV: Distribution of mRS* at 3−6 months by randomized treatment allocation, by stroke severity (among all randomized patients)
